Physical Treatment Patents (Class 530/427)
  • Patent number: 6844321
    Abstract: Crystals of glucagon-like peptide-1 (GLP-1) and GLP-1 analogues, and processes for preparation of crystals of GLP-1 and GLP-1 analogues.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: January 18, 2005
    Assignee: Novo Nordisk A/S
    Inventor: Anne Charlotte Arentsen
  • Patent number: 6841659
    Abstract: A method for extracting proteins from the intercellular space of plants is provided. The method is applicable to the large scale isolation of many active proteins of interest synthesized by plant cells. The method may be used commercially to recover recombinantly produced proteins from plant hosts thereby making the large scale use of plants as sources for recombinant protein production feasible.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: January 11, 2005
    Assignee: Large Scale Biology Corporation
    Inventors: Thomas H. Turpen, Stephen J. Garger, Michael J. McCulloch, Terri I. Cameron, Michelle L. Samonek-Potter, R. Barry Holtz
  • Patent number: 6780979
    Abstract: The invention concerns a method for purifying PrPres from a biological sample to be used for qualitative and/or quantitative determination of the PrPres in said sample. The method essentially consists in: (1) incubating, during 30 seconds to 2 hours, at a temperature less than 80° C.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: August 24, 2004
    Assignee: Commissariat a l'Energie Atomique
    Inventor: Jean-Philippe Deslys
  • Patent number: 6759521
    Abstract: A method to select and prepare polymorphs of materials by switching the polarization state of light employing non-photochemical laser-induced nucleation.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: July 6, 2004
    Inventors: Allan S. Myerson, Bruce A. Garetz
  • Patent number: 6756482
    Abstract: The present invention provides a process for purifying human activin by cation exchange chromatography and chaotropic ion concentration gradient elution.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: June 29, 2004
    Assignee: Ajinomoto Co., Inc.
    Inventors: Kunio Ono, Shigekatsu Tsuchiya, Daisuke Ejima, Yuzuru Eto
  • Patent number: 6747132
    Abstract: The present invention employs a filtration step during the hemoglobin purification process that substantially decreases viral contamination of a hemoglobin solution. The filtration means can be used to separate hemoglobin and several endogenous antioxidant enzymes from red blood cell stroma and potential adventitious agents. The purified hemoglobin/antioxidant composition is then subjected to a chemical modification process. The resulting modified hemoglobin/antioxidant composition is then fractionated to remove unmodified hemoglobin species and residual reactants, formulated in electrolytes and rendered sterile. The resulting modified hemoglobin product is substantially free of viral contamination and contains at least one endogenous antioxidant enzyme that retains antioxidant activity.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: June 8, 2004
    Assignee: Apex Biosciences, Inc.
    Inventors: Christopher Thomas Privalle, Cyrus John Stacey, Todd Lewis Talarico
  • Patent number: 6740740
    Abstract: The present invention features a method for isolating and purifying proteins and peptides of interest from a plant host, which is applicable on a larger scale. Moreover, the present invention provides a more efficient method for isolating proteins and peptides of interest than those methods described in the prior art. In general, the present method of isolating proteins and peptides of interest comprises the steps of homogenizing a plant to produce a green juice, adjusting the pH of and heating the green juice, separating the target protein/peptide from other components of the green juice by one or more cycles of centrifugation and/or resuspension, and finally purifying proteins and peptides by such procedures as chromatography and/or salt precipitation.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: May 25, 2004
    Assignee: Large Scale Biology Corporation
    Inventors: Stephen J. Garger, R. Barry Holtz, Michael J. McCulloch, Thomas H. Turpen
  • Patent number: 6734210
    Abstract: Stable salts of azelaic acid with polycations such as chitosan are described. The salts according to the invention are water-soluble, therapeutically more efficacious and are valuable for use as active constituents in pharmaceutical as well as cosmeceutical compositions.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: May 11, 2004
    Inventor: Rolland F. Hebert
  • Patent number: 6670454
    Abstract: The present invention relates to crosslinking of porous materials made of biodegradable polymers. The method comprises: (a) placing a porous biodegradable polymer in a chamber; (b) introducing a supercritical fluid containing a crosslinking agent into the chamber to effect crosslinking of the porous biodegradable polymer; and optionally (c) introducing a pure supercritical into the chamber to wash the crosslinked polymer until the crosslinking agent is substantially removed from the polymer.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: December 30, 2003
    Assignee: Industrial Technology Research Institute
    Inventors: Huey-Min Lai, Kuang-Rong Lee, Chin-Chin Tsai, Hsi-Hsin Shih, Yuan-Chia Chang
  • Patent number: 6660495
    Abstract: The present invention relates to a process for the controlled enzymatic cleavage of purified and depigmented active allergenic proteins from indoor and outdoor source materials, which process produces fragments of allergens that retain the natural T-lymphocyte stimulating epitopes, but are depleted of IgE-binding B-cell epitopes and complement-activating agents. The invention also relates to the new pharmaceutical products. These allergen fragments do not exhibit the disadvantages of conventional allergenic extracts for immunotherapy and can be safely used to induce a state of specific T-cell anergy and immunological tolerance in allergic human beings.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: December 9, 2003
    Assignee: C.B.F. Leti, S.A.
    Inventors: Lubertus Berrens, Maria Leticia Gonzales Romano, Maria Teresa Gallego Camara
  • Patent number: 6617435
    Abstract: A method for extracting proteins from the intercellular space of plants is provided. The method is applicable to the large scale isolation of many active proteins of interest synthesized by plant cells. The method may be used commercially to recover recombinantly produced proteins from plant hosts thereby making the large scale use of plants as sources for recombinant protein production feasible.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: September 9, 2003
    Assignee: Large Scale Biology Corporation
    Inventors: Thomas H. Turpen, Stephen J. Garger, Michael J. McCulloch, Terri I. Cameron, Michelle L. Samonek-Potter, R. Barry Holtz
  • Patent number: 6610831
    Abstract: Methods and apparatus for recovering zein from substrates are disclosed. The method includes extracting a zein-containing substrate such as whole corn with ethanol to yield a crude zein alcoholic dispersion and treating this dispersion with an adsorbent to remove at least one of starch, color or oil to yield a purified zein which is subsequently recovered or used in industrial applications. A preferred adsorbent is activated charcoal.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: August 26, 2003
    Assignee: Lurgi PSI, Ltd.
    Inventors: Jerel McInnis, Qingnong Tang
  • Patent number: 6602985
    Abstract: Zein is recovered from gluten meal prepared by wet milling procedures by washing the gluten with clean water to remove water-soluble components; separating the water-soluble components and recovering the water-insoluble components; extracting the water insoluble components with hydrous ethanol solvent to extract zein; recovering the crude zein extract; treating the crude zein extract with an adsorbent that adsorbs at least one of color, odor, oil and fatty acid; and to yield a purified zein extract.
    Type: Grant
    Filed: February 10, 2000
    Date of Patent: August 5, 2003
    Assignee: Lurgi PSI, Inc.
    Inventors: Jerel McInnis, Qingnong Tang
  • Patent number: 6590081
    Abstract: Pure, stable crystalline forms of parathyroid hormone, particularly teriparatide, are described as well as methods of preparation and purification.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: July 8, 2003
    Assignee: Eli Lilly and Company
    Inventor: Faming Zhang
  • Patent number: 6579723
    Abstract: A method for purifying factor VIII/vWF complex or free vWF by immunoaffinity chromatography in a form suitable for use as a medicament. Factor VIII/vWF complex or free vWF is recovered from an immunoaffinity adsorbent by using an eluting agent containing a zwitterionic species. The presence of the zwitterionic species allows for the use of mild conditions throughout the preparation, facilitating retention of molecular integrity, activity, and incorporation of the recovered proteins into pharmaceutical preparations without the need for additional stabilizers or preservatives.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: June 17, 2003
    Assignee: Baxter Aktiengesellschaft
    Inventors: Artur Mitterer, Christian Fiedler, Bernhard Fischer, Friedrich Dorner, Johann Eibl
  • Patent number: 6569999
    Abstract: A method for activating a denatured protein, includes the steps of: adding a detergent to the denatured protein to allow a protein-detergent complex to be formed; and adding high-molecular weight amylose to the protein-detergent complex so that the high-molecular weight amylose removes the detergent.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: May 27, 2003
    Assignee: National Food Research Institute, Ministry of Agriculture, Forestry and Fisheries
    Inventors: Sachiko Machida, Kiyoshi Hayashi, Takeshi Takaha, Yoshinobu Terada, Kazutoshi Fujii
  • Patent number: 6566490
    Abstract: Disclosed is a method for producing seeding microcrystals for the production of human insulin, the microcrystals being free of non-human pancreatic insulin, the method comprising providing an unseeded suspension of human insulin, the suspension being free of non-human pancreatic insulin, and homogenizing the insulin suspension under pressure to result in human insulin microcrystals suitable for use as seeding microcrystals for the production of zinc insulin products. The method of homogenization under pressure may also be used for the production of seeding mnicrocrystals for other peptides and proteins, in particular pharmaceutical peptides or proteins such as insulin, GLP-1, glucagon and growth hormones.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: May 20, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Flemming Manique, Christian Ilsoe
  • Patent number: 6562952
    Abstract: A process for forming small micron-sized (1-10 &mgr;m) protein particles is provided wherein a protein, a solvent system for the protein and an antisolvent for the protein solvent system are contacted under conditions to at least partially dissolve the protein solvent system in the antisolvent, thereby causing precipitation of the protein. The solvent system is made up of at least in part of a halogenated organic alcohol, most preferably 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP). Preferably, a solution of the protein in the solvent system is sprayed through a nozzle into a precipitation zone containing the antisolvent (preferably CO2) under near- or supercritical conditions.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: May 13, 2003
    Assignee: The University of Kansas
    Inventors: Roger A. Rajewski, Bala Subramaniam, William K. Snavely, Fenghui Niu
  • Publication number: 20030027997
    Abstract: Crystal growth can be initiated and controlled by dynamically controlled vapor diffusion or temperature change. In one aspect, the present invention uses a precisely controlled vapor diffusion approach to monitor and control protein crystal growth. The system utilizes a humidity sensor and various interfaces under computer control to effect virtually any evaporation rate from a number of different growth solutions simultaneously by means of an evaporative gas flow. A static laser light scattering sensor can be used to detect aggregation events and trigger a change in the evaporation rate for a growth solution. A control/follower configuration can be used to actively monitor one chamber and accurately control replicate chambers relative to the control chamber. In a second aspect, the invention exploits the varying solubility of proteins versus temperature to control the growth of protein crystals.
    Type: Application
    Filed: October 9, 2002
    Publication date: February 6, 2003
    Inventors: Terry L. Bray, Larry J. Kim, Michael Harrington, Lawrence J. Delucas, Wilbur William Wilson
  • Patent number: 6506725
    Abstract: A blood substitute and plasma expander comprising a cross-linked, substantially endotoxin-free hemoglobin solution and process for preparing same. The process comprises fractionating whole blood, separating out a stromal-free, sterile hemoglobulin solution, chromatographically separating endotoxins from said hemoglobin solution and crosslinking the resulting endotoxin-free hemoglobin solution.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: January 14, 2003
    Assignee: BioPure Corporation
    Inventors: Carl W. Rausch, Mario Feola
  • Patent number: 6504085
    Abstract: A method for extraction of heterologous protein from plant seed comprises extracting the germ portion of the seed and extracting and purifying the protein from the germ. Enhanced expression in the germ is provided, and allows for improved efficiency in production, and cost savings. Directing expression to the germ portion further increases expression levels of the protein. The ubiquitin promoter preferentially directs expression to the germ portion of plant seed.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: January 7, 2003
    Assignee: ProdiGene, Inc.
    Inventor: John A. Howard
  • Patent number: 6498141
    Abstract: A process is disclosed for the preparation of an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: December 24, 2002
    Assignee: Northfield Laboratories, Inc.
    Inventors: Richard E. DeWoskin, Marc D. Doubleday
  • Patent number: 6489450
    Abstract: The present disclosure provides an effective method for the refolding of denatured proteins in solution so that properly folded, biologically active protein in solution is recovered in high yield. The refolding takes place at pressures between about 0.25 kbar to about 3.5 kbar, advantageously at about 1.5 kbar to about 3 kbar. Typically a chaotropic agent is present at a concentration which is not effective for denaturing protein at atmospheric pressure, and optionally, oxidation-reduction reagents can be incorporated in the refolding solution so that native intramolecular disulfide bonds can be formed where that is desired. The method is applicable to substantially all proteins, especially after solubilization and/or denaturation of insoluble protein aggregates, inclusion bodies, or abnormal oligomeric (soluble) aggregates.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: December 3, 2002
    Assignee: University Technology Corporation
    Inventors: Theodore W. Randolph, John F. Carpenter, Richard St. John
  • Patent number: 6479636
    Abstract: A method of extracting and purifying recombinant protein(s) from transgenic sugarcane is disclosed. Fractioning of sugarcane juice that has been extracted from the cane stalks is obtained by using a multiple stage filtering process that uses multiple stages of decreasing porosity (preferably screening) followed by preferably membrane type filters, ion exchange, membrane adsorber, and chromatographic processes.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: November 12, 2002
    Assignees: Honiron Corporation (a Louisiana Corporation), The Texas A&M University (an Agency of the State of Texas)
    Inventors: T. Erik Mirkov, Jean P. Monclin, Adam Barrilleaux, James E. Irvine, Francis Moonan
  • Patent number: 6454950
    Abstract: A method for the separation of a predetermined compound comprising i) partitioning the compound in a two-phase (system A) in which at least one of the phases is rich (phase 1) and the other is poor (phase 2) in a thermoseparating polymer (I), ii) collecting one phase (phase 1 or phase 2) containing said compound, and iii if desired, further working up said compound from the phase collected in step ii, characterized a) in that polymer (I) is a micell-forming thermoseparating polymer, and b) in that phase 2 possibly contains at least one agent that is cloud point-decreasing for thermoseparating polymer (I), such as a polymer (II) that is incompatible with polymer (I) or a salt.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: September 24, 2002
    Assignee: Amersham Pharmacia Biotech AB
    Inventors: Folke Tjerneld, Josefine Persson, Hans Olof Johansson
  • Patent number: 6441147
    Abstract: A method for extracting proteins from the intercellular space of plants is provided. The method is applicable to the large scale isolation of many active proteins of interest synthesized by plant cells. The method may be used commercially to recover recombinantly produced proteins from plant hosts thereby making the large scale use of plants as sources for recombinant protein production feasible.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 27, 2002
    Assignee: Large Scale Biology Corporation
    Inventors: Thomas H. Turpen, Stephen J. Garger, Michael J. McCulloch, Terri I. Cameron, Michelle L. Samonek-Potter, R. Barry Holtz
  • Patent number: 6437101
    Abstract: Methods are provided in this invention for the isolation of human growth hormone, growth hormone antagonist, or a homologue of either, from a biological source. The methods of the invention use multi-phase extraction.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: August 20, 2002
    Assignee: Akzo Nobel N.V.
    Inventors: Kirk James Hayenga, Pascal P. Valex
  • Patent number: 6426406
    Abstract: A method to prepare new or unexpected polymorphs of materials which have not been observed, or to obtain a known polymorph under different conditions than those in which it is usually made, by using a laser to cause nucleation and crystal growth to occur in a supersaturated solution in such a way as to obtain a crystal structure which would not normally appear without the use of the laser.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: July 30, 2002
    Inventors: Allan S. Myerson, Bruce A. Garetz
  • Patent number: 6387877
    Abstract: The invention relates to a method of removing endotoxin from preparations of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this deprogenation step, and to the depyrogenated product and its clinical uses.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: May 14, 2002
    Assignee: National Blood Authority
    Inventors: John Edward More, Jacqueline Rott, David Roger Lewin
  • Publication number: 20020025343
    Abstract: A process is disclosed for the preparation of an essentially tetramerfree, substantially stromafree, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramerfree, substantially stromafree, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.
    Type: Application
    Filed: May 10, 1999
    Publication date: February 28, 2002
    Inventors: RICHARD E. DE WOSKIN, MARC D. DOUBLEDAY
  • Patent number: 6350590
    Abstract: The present invention relates to a process for the controlled enzymatic cleavage of purified and depigmented active allergenic proteins from indoor and outdoor source materials, which process produces fragments of allergens that retain the the natural T-lymphocyte stimulating epitopes, but are depleted of IgE-binding B-cell epitopes and complement-activating agents. The invention also relates to the new pharmaceutical products. These allergen fragments do not exhibit the disadvantages of conventional allergenic extracts for immunotherapy and can be safely used to induce a state of specific T-cell anergy and immunological tolerance in allergic human beings.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: February 26, 2002
    Assignee: C.B.F. Leti, S.A.
    Inventors: Lubertus Berrens, Maria Leticia Gonzales Romano, Maria Teresa Gallego Camara
  • Patent number: 6342367
    Abstract: Disclosed is an economical method for the preparation of chondroitin sulfates A and C useful as an effective ingredient of medicaments from fish scales as a waste material discharged from fishery in large quantities. Fish scales are enzymatically decomposed in an aqueous medium in the presence of a protease to isolate the chondroitin sulfate compounds and by-product polypeptides followed by removal of the by-product polypeptides from the aqueous solution by a cation-exchange treatment and then the aqueous solution of the chondroitin sulfate compounds is subjected to fractional precipitation by the addition of ethyl alcohol as the precipitant.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: January 29, 2002
    Assignee: Japan as represented by Secretary of Agency of Industrial Science and Technology
    Inventors: Toshihisa Sumi, Hideki Ohba, Toru Ikegami, Masao Shibata, Tsuyoshi Sakaki, Imre Sallay, Sung Soo Park
  • Patent number: 6337389
    Abstract: The present invention relates to a process for the production of marine invertebrate type V telopeptide containing collagen preparations from marine invertebrates, compositions containing preparations, and methods of using these preparations. The collagen preparation includes telopeptide containing and optionally invertebrate atelopeptide containing, type V fibrillar collagen. The present collagen preparations may be employed in a variety of products including for example, cosmetic, pharmacological, dental, and cell culture products.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: January 8, 2002
    Assignee: BioScience Consultants, L.L.C.
    Inventor: Lloyd Wolfinbarger, Jr.
  • Publication number: 20010055617
    Abstract: The present invention concerns processes for the production of dry, partially amorphous products containing biologically active and in particular therapeutically active material which are macroscopically homogeneous substance mixtures, the substance mixtures being selected from at least one substance of each of the groups
    Type: Application
    Filed: April 27, 1998
    Publication date: December 27, 2001
    Inventors: MARKUS MATTERN, GERHARD WINTER
  • Patent number: 6326029
    Abstract: A resorbable extracellular matrix for reconstruction of cartilage tissue, the matrix being substantially free from non-native collagen, and including a purified collagen II material formed form natural cartilage and having fibers of native collagen II which are physiologically acceptable for implant into a mammalian body.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: December 4, 2001
    Assignee: Ed Geistlich Soehne AG fuer Chemische Industrie
    Inventors: Peter Geistlich, Myron Spector, Zdenek Eckmayer
  • Patent number: 6323326
    Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: November 27, 2001
    Assignees: Chiron Corporation, G. D. Searle & Co.
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan K. Rana, Maninder S. Hoba, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Patent number: 6319896
    Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: November 20, 2001
    Assignees: Chiron Corporation, G.D. Searle & Co.
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Patent number: 6313268
    Abstract: This invention is directed to a novel &bgr;-secretase that produces the A&bgr; peptide found in Alzheimer's Disease. One &bgr;-secretase is a protein having a molecular weight of about 61, 81 or 88 kDa that cleaves an amyloid precursor protein (APP) substrate. Another is a protease complex having a molecular between about 180 and 200 kDa, which, in one embodiment, contains the 61, 81, and 88 kDa proteins and, in another embodiment, contains proteins having a molecular weight of about 66, 60, 33 and 29 kDa. Another &bgr;-secretase has a molecular weight between about 50 and 90 kDA. The invention is also directed to methods of selecting agents that inhibit A&bgr; peptide production and treating Alzheimer's disease in patients.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: November 6, 2001
    Inventor: Vivian Y. H. Hook
  • Publication number: 20010034066
    Abstract: A method of protein precipitation, concentration and removal of non-protein agents from the protein solution wherein the protein solution is treated with a protein-precipitation agent containing an acidic agent, a salt and a precipitate forming agent. After precipitation, the protein precipitate is washed with a water miscible organic solvent agent to remove non-protein agents present in the protein precipitate.
    Type: Application
    Filed: April 27, 2001
    Publication date: October 25, 2001
    Inventor: Aftab Alam
  • Patent number: 6284875
    Abstract: A method for extracting proteins from the intercellular space of plants is provided. The method is applicable to the large scale isolation of many active proteins of interest synthesized by plant cells. The method may be used commercially to recover recombinantly produced proteins from plant hosts thereby making the large scale use of plants as sources for recombinant protein production feasible.
    Type: Grant
    Filed: February 9, 2000
    Date of Patent: September 4, 2001
    Assignee: Large Scale Biology Corporation
    Inventors: Thomas H. Turpen, Stephen J. Garger, Michael J. McCulloch, Terri I. Cameron, Michelle L. Samonek-Potter, R. Barry Holtz
  • Patent number: 6281337
    Abstract: The present invention provides methods for isolating adjunct isoforms of proteins and converting them to the desired protein. In preferred embodiments, the present invention contemplates the use of acid solutions or zinc solutions to cleave a chemical group from a desired protein. In further preferred embodiments, the present invention contemplates the oxidation of reduced sulfhydryl groups with cleavage of chemical groups to form a functional desired protein.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: August 28, 2001
    Assignee: Schering Corporation
    Inventors: Susan Cannon-Carlson, Andres Frei, Seoju Lee, Roland Mengisen, Marcio Voloch, David C. Wylie
  • Patent number: 6239262
    Abstract: A method for purification of proteins by displacement chromatography in hydrophobic interaction and reversed phase chromatographic systems uses low molecular weight (less than about 10,000) surface-active compounds as displacers. Examples of effective displacers are benzethonium chloride, benzyltributylammonium chloride, and tetrahexylammonium chloride.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: May 29, 2001
    Assignee: Rensselaer Polytechnic Institute
    Inventors: Steven M. Cramer, Abhinav A. Shukla, Khurram M. Sunasara
  • Publication number: 20010001657
    Abstract: One can impart outstanding resistance against collapse under pressure to gas-filled microvesicle used as contrast agents in ultrasonic echography by using as fillers gases whose solubility in water, expressed in liter of gas by liter of water under standard conditions, divided by the square root of the molecular weight does not exceed 0.003.
    Type: Application
    Filed: April 4, 1997
    Publication date: May 24, 2001
    Inventors: MICHEL SCHNEIDER, FENG YAN, PASCAL GRENIER, NADINE GARCEL, JEROME PUGINIER, MARIE-BERNADETTE BARRAU
  • Patent number: 6210574
    Abstract: A system for separating nucleated cells from a blood sample includes a charge-flow separator (CFS), which separates blood into fractions according to the surface charge density characteristics coupled with an affinity-filtration separator which either outputs a separated blood fraction to the CFS or receives a separated blood fraction from the CFS. The system permits separation of nucleated fetal red blood cells, erythroid progenitor cells and other nucleated cells found in blood samples.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: April 3, 2001
    Assignee: BioSeparations, Inc.
    Inventors: David W. Sammons, Garland E. Twitty, Joseph G. Utermohlen, Rizwan Sharnez
  • Patent number: 6197935
    Abstract: The use of collagen as a biomedical implant raises safety issues towards viruses and prions. The physicochemical changes and the in vitro and in vivo biocompatibility of collagen treated with heat, and by formic acid (FA), trifluoroacetic acid (TFA), tetrafluoroethanol (TFE) and hexafluoroiso-propanol (HFIP) were investigated. FA and TFA resulted in extensive depurination of nucleic acids while HFIP and TFE did so to a lesser degree. The molecules of FA, and most importantly of TFA, remained within collagen. Although these two acids induced modification in the secondary structure of collagen, resistance to collagenase was not affected and, in vitro, cell growth was not impaired. Severe dehydrothermal treatment, for example 110° C. for 1-3 days under high vacuum, also succeeded in removing completely nucleic acids. Since this treatment also leads to slight cross-linking, it could be advantageously used to eliminate prion and to stabilize gelatin products.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: March 6, 2001
    Assignee: DiagnoCure, Inc.
    Inventors: Charles Doillon, Régen Drouin, Gaétan LaRoche
  • Patent number: 6162904
    Abstract: A process for producing an intravenously-administrable gamma globulin solution substantially free of contaminating viruses by heat treating for viral inactivation and fractionating an impure gamma globulin solution and then treating the purified gamma globulin with a solvent-detergent for further viral inactivation. In a continuous process disclosed herein, partially purified gamma globulin solids is not recovered as an intermediate product during the disclosed process. In the continuous process, the fractionation to obtain a purified gamma globulin solution is carried out without precipitation of the desired gamma globulin.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: December 19, 2000
    Assignee: Alpha Therapeutic Corporation
    Inventors: Raja R. Mamidi, Andranik Bagdasarian, Gorgonio Canaveral, Kazuo Takechi
  • Patent number: 6160097
    Abstract: A process is described for reactivating purified membrane proteins in which a mixture composed of membrane protein, a phospholipid and a detergent is frozen and subsequently thawed.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: December 12, 2000
    Assignee: Dade Behring Marburg GmbH
    Inventor: Norbert F. Zander
  • Patent number: 6136959
    Abstract: A process for isolating edible protein from animal muscle by solubilizing the protein in an alkaline aqueous solution is disclosed.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: October 24, 2000
    Assignee: University of Massachusetts
    Inventors: Herbert O. Hultin, Stephen D. Kelleher
  • Patent number: RE37872
    Abstract: A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: October 8, 2002
    Assignee: Inhale Therapeutics Systems, Inc.
    Inventors: Felix Franks, Ross H. M. Hatley
  • Patent number: RE38385
    Abstract: A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: January 13, 2004
    Assignee: Nektar Therapeutics
    Inventors: Felix Franks, Ross H. M. Hatley